ArticleVeterinary immunology and immunopathology1990
Recombinant porcine interferon-gamma activates in vitro porcine adherent mononuclear cells to produce interleukin 1.
Article in Veterinary immunology and immunopathology, 1990. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 12 citations in OpenAlex.
- The porcine innate immune system: an update.Developmental and comparative immunology · 2014Review
- Article
- Cloning of porcine cytokine-specific cDNAs and detection of porcine tumor necrosis factor alpha, interleukin 6 (IL-6), and IL-1 beta gene expression by reverse transcription PCR and chemiluminescence hybridization.Clinical and diagnostic laboratory immunology · 1995Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The effect of recombinant porcine interferon-gamma (rPoIFN gamma) on in vitro production of interleukin 1 (IL-1) by porcine blood monocytes was studied. Three-day-old cultures of porcine adherent blood mononuclear cells were treated by doses of rPoIFN gamma for 3 or 6 days before lipopolysaccharide (LPS)-induction. While rPoIFN gamma alone had no effect, a combined treatment by rPoIFN gamma and LPS enhanced the IL-1 secretory potential of adherent mononuclear cells and, to a lesser extent, the level of cell-associated IL-1. The IL-1 activity was neutralized by anti porcine IL-1 alpha and beta antisera. These results demonstrate that rPoIFN gamma has immunomodulatory effects in vitro on porcine monokine production.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.